CANbridge Pharmaceuticals has appointed Glenn Hassan as Chief Financial Officer and Chief Business Officer, and Dr Gerald F. Cox in an advisory capacity as Chief Development Strategist and Interim Chief Medical Officer.
Mr Hassan brings a broad range of banking and investment experience in the healthcare and global therapeutics sector to his role at CANbridge.
Most recently, Mr Hassan was Director at Cross Border Healthcare Investment Banking at China Renaissance Capital, focused on advising US and greater China life science companies on capital-raising activities and led the US equity capital market activities for the healthcare sector.
Prior to founding his consulting practice, Dr Cox was Chief Medical Officer for Editas Medicine in Cambridge, where he led the clinical development of CRISPR-based genome editing medicines to treat human diseases, resulting in the first IND approval for in vivo delivery of CRISPR/Cas9 gene editing.
He also had a long stint at Sanofi Genzyme, culminating as Vice President of Rare Disease Clinical Development, where he oversaw multiple global rare disease clinical development programs.
James Xue, founder, Chairman and CEO of CANbridge Pharmaceuticals, said: “With this strong partnership in place, we will lead CANbridge’s growth and transformation into a Chinese sector leader with a global impact in rare disease and specialty care.”